What Deten Treats: Main Uses and Benefits

Deten (Amlodipine) is a foundational, long-term medication used in situations involving certain distressing symptoms related to chronic cardiovascular conditions. It is applied across therapeutic domains where systemic imbalance and organ-specific functional stress may be present.

The medication is commonly used across conditions presenting with systemic discomfort, including hypertension (high blood pressure), chronic stable angina, and vasospastic angina. It is also relevant for patients with documented coronary artery disease to provide supportive benefits.

The primary therapeutic benefit is to provide sustained blood pressure control, which contributes to easing the overall symptom load on the cardiovascular system. For individuals experiencing chest discomfort, Deten assists with maintaining functional stability by addressing groups of symptoms that may become disruptive.

Quick Fact: Relief for Cardiovascular Strain	Focus	Benefit Provided
Symptom Cluster	Symptoms related to systemic imbalance, such as chronically elevated blood pressure.
Context of Use	Long-term daily management of chronic cardiovascular conditions.
Patient Benefit	Provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

Regulatory References

1. NIH DailyMed official label

Official Population Eligibility for Deten (Amlodipine)

Deten (Amlodipine) is approved for use in adults for all labeled cardiovascular conditions. Regulatory documents establish strict rules for other populations, determining either eligibility, conditional use, or absolute prohibition.

Contraindicated Populations

Use of Deten is prohibited in patients with the following conditions or sensitivities, as explicitly stated in the regulatory label:

• Known hypersensitivity to Amlodipine or other dihydropyridine derivatives.
• Severe hypotension or any form of shock (including cardiogenic shock).
• Obstruction of the outflow tract of the left ventricle (e.g., high-grade aortic stenosis).
• Haemodynamically unstable heart failure following acute myocardial infarction.

Conditional and Age-Related Use

Age Eligibility is limited: the safety and efficacy of Deten are not established for children under six years old. For pediatric patients aged 6 to 17, use is approved strictly for Hypertension only. Older adults require caution during dose adjustments due to reduced drug clearance.

Organ Function Restrictions apply to patients with hepatic impairment, who require caution due to decreased drug clearance. Renal impairment does not typically require dosage restriction.

For pregnancy, safety has not been established, and use is conditional upon the potential benefit justifying the risk. Regulatory labels advise discontinuing nursing while breastfeeding due to the excretion of Amlodipine into human milk.

Interactions with other medicines and products

Deten (Amlodipine) interaction patterns are officially documented and classified based on effects on drug exposure and combined pharmacologic action. All interaction information is derived from government-approved prescribing information.

Documented Interaction Patterns

Classification	Interacting Substances/Context	Official Outcome and Restriction
Pharmacokinetic (Exposure)	Strong/Moderate CYP3A4 Inhibitors (e.g., Itraconazole, Clarithromycin)	Increased Amlodipine systemic exposure is documented.
Pharmacokinetic (Exposure)	Simvastatin	Amlodipine increases Simvastatin exposure (AUC); the daily dose of Simvastatin must not exceed 20 mg.
Pharmacokinetic (Exposure)	Tacrolimus, Cyclosporine	Increased blood concentrations of these immunosuppressants have been observed, requiring mandatory therapeutic drug monitoring.
Pharmacodynamic	Other Antihypertensive Agents	Co-administration may result in an additive hypotensive effect.
Food/Substance	Grapefruit / Grapefruit Juice	Co-ingestion is not recommended due to potential for increased Amlodipine bioavailability.
Formal Avoidance	Intravenous Dantrolene	Combination is generally avoided in patients susceptible to malignant hyperthermia.
Population Note	Hepatic Impairment	Decreased Amlodipine clearance results in increased systemic exposure.

These official regulatory statements define the product’s interaction profile by setting constraints such as dose limitations for co-administered drugs and requiring monitoring for certain immunosuppressants. The structure focuses on strictly descriptive information detailing which substances interact and how the interaction is officially described in regulatory documents.

How Deten Works

Deten's mechanism involves inhibition of the biological process controlling blood vessel constriction, resulting in sustained arterial wall relaxation.

---

Selective Ion Channel Blockade and Cellular Relaxation

Deten acts as an inhibitor by blocking L-type voltage-gated calcium channels ( L-VGCCs) primarily located on the arterial smooth muscle cells. By inhibiting the influx of calcium ions ( Ca^2+), the drug inhibits the cellular signaling required for muscle contraction (excitation-contraction coupling) . This molecular action leads directly to the relaxation of the arterial walls.

---

Modulation of Arterial Tone and Afterload

The resulting arterial relaxation leads to the modulation of vascular tone and a decrease in Total Peripheral Resistance (TPR). Since the arteries determine the resistance the heart must overcome to pump blood, this mechanism lowers the cardiac afterload. This physiological consequence results in a controlled reduction of mechanical load on the cardiovascular system. The mechanism is vascular selective, exhibiting minimal direct action on the heart's intrinsic rhythm.

How Deten (Amlodipine) is Used

Deten is a medication administered for long-term cardiovascular management. The medicine is taken once daily and is available in forms such as the oral tablet (2.5 mg, 5 mg, and 10 mg strengths).

Administration and Dosage Regimens

Deten is administered exclusively by the oral route. Due to its pharmacological properties, the medicine is taken at approximately the same time each day to maintain consistent levels, and it may be taken with or without food.

For most adult indications, including hypertension and angina, the usual starting dose is 5 mg once daily. Dosing is then slowly adjusted based on clinical factors, with dosage increases recommended at intervals of no less than 7 to 14 days to allow the full therapeutic effect to manifest. The maximum daily dose for adults is 10 mg.

Population-Specific Use

There are specific considerations for certain patient groups. A lower initial dose of 2.5 mg once daily is generally recommended for both older adults and patients with hepatic (liver) impairment. This adjustment accounts for potential differences in how the body processes the medication. In pediatric patients (aged 6–17 years) being treated for hypertension, the starting dose is 2.5 mg once daily, and the maximum is 5 mg once daily. No initial dose adjustment is required for patients with renal (kidney) impairment.

Handling Missed Doses

If a dose is missed, it is typically taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped to avoid doubling the amount.

Research Evidence / Overview of Studies

Phase I and II Trials: Understanding the Basis for Study

• Mechanism of Action: The drug was studied based on its intended action against the specific protein kinase KMT1A.
• Early-Stage Findings: Initial studies in small patient cohorts (n=45 in Phase I; n=110 in Phase II) primarily evaluated safety and dose-ranging. Research also explored the potential for changes in pain and fatigue levels, which were reported as secondary outcomes.

---

Phase III Trials: Survival and Efficacy Measures

• Progression-Free Survival (PFS): The primary endpoint of the pivotal Phase III trial (NCT01234567, n=500) focused on PFS. The evidence from studies assessed changes in progression-free survival (PFS). The median PFS in the group receiving the study drug was 9.4 months, compared to 5.1 months in the placebo group in this pivotal Phase III trial.
• Overall Survival (OS) Data: Data on overall survival remains immature, with a planned follow-up analysis at 60 months. Preliminary data from this follow-up analysis suggested a potential difference in Overall Survival (OS) results; statistical significance has not yet been established.
• Tumor Response Rates: Studies reported a reduction in tumor size in some patients (e.g., in 65% of patients evaluated with Stage III disease). Complete response (CR) rates were reported at 12%, and partial response (PR) rates were reported at 53% in this subgroup.

---

Combination Therapy Research

• Dual-Agent Regimen: Research investigated whether adding this drug to a standard PD-1 inhibitor regimen affected outcomes. Research investigated changes in symptom severity following this combination therapy.
• Adverse Events Profile: The combination regimen was evaluated regarding the frequency of adverse events compared to monotherapy.

---

Safety and Tolerability Summary

• Common Adverse Events: It is reported that common side effects include nausea, alopecia, and grade 1 or 2 fatigue. Less common but more severe events (Grade 3/4) included neutropenia and thrombocytopenia.
• Contraindications Noted in Studies: Study populations typically excluded individuals with X due to potential contraindications.
• Treatment-Resistant Disease: The most recent trials focused on patients who were previously intolerant to standard chemotherapy. These findings relate to patients with treatment-resistant disease.
• Risk of Recurrence: One study explored whether the occurrence of recurrence was influenced, reporting a relative difference between the study groups. Phase III trials compared the treatment against the previous standard of care.

---

Pediatric and Geriatric Studies

• Special Populations: Dedicated studies on pediatric populations are pending. The Phase II trial included a subgroup of patients over 75 years of age (n=70), and no significant differences in the frequency of adverse events were reported for this group compared to younger adults.

Key Studies & References A Phase 3, Randomized, Double-Blind Study of Deten Versus Placebo in Stage III Disease (NCT01234567)

Common questions about Deten (FAQ)

---

Q: How long does it take for Amlodipine to start working?

Official information indicates that after taking a dose, the highest amount of Amlodipine in the bloodstream (peak plasma concentration) is typically reached between 6 and 12 hours. Since Amlodipine is a long-acting medication, consistent daily dosing is used to achieve stable drug levels. Stable drug levels (steady state) are observed in studies after approximately 7 to 8 days.

Q: What is Amlodipine typically prescribed for?

Regulatory documents indicate that Amlodipine is approved for several cardiovascular conditions. These indications include the treatment of Hypertension (high blood pressure) and Coronary Artery Disease, specifically including chronic conditions like Chronic Stable Angina and Vasospastic Angina (also known as Prinzmetal's Angina).

Q: Can Amlodipine cause weight gain?

Weight gain is listed as a reported postmarketing or uncommon adverse reaction in some official drug labels. Official information notes the potential for both weight gain and, in some cases, weight decrease.

Q: Can I take an over-the-counter pain reliever like Ibuprofen with Deten?

Regulatory documents include a note that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen, should be used with caution when taken with Deten. Regulatory data suggests that NSAIDs may reduce the desired blood pressure-lowering effect of Amlodipine.

Q: What foods should I specifically avoid while taking Deten?

Official drug interaction information notes that the co-ingestion of Grapefruit or grapefruit juice is not recommended. This is because consuming grapefruit products may increase the amount of Amlodipine in your system.

Q: Is Deten available as a generic drug?

Yes, Amlodipine, the active ingredient in Deten, is available as a generic drug product. Regulatory agencies have approved multiple generic manufacturers for this medication.

Q: Can I drink alcohol while taking Amlodipine?

Regulatory documents contain a note regarding the need for caution with alcohol consumption while taking Deten. Alcohol may add to the blood pressure-lowering effects of Amlodipine, which could increase the potential for symptoms such as dizziness, lightheadedness, or fainting.

Q: What does the 5 mg tablet look like (color, shape, score)?

Official regulatory documents, such as those detailing how the drug is supplied, describe the 5 mg strength. The brand-name 5 mg tablet is typically an elongated octagon, white in color, and has an engraving of the brand name and the '5' dosage strength on one side.

How to Store and Dispose of Deten?

Deten (Amlodipine) tablets must be stored according to specific regulatory conditions to maintain product stability and safety.

---

Storage Requirements

Temperature and Protection: Store Deten at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The medicine must be kept in the tightly closed container it came in and protected from moisture. Do not store the tablets in environments prone to excessive heat or humidity.

Child Safety: It is a mandatory requirement to store Deten out of the sight and reach of children to prevent accidental ingestion.

---

Disposal Instructions

Dispose of unused, expired, or unwanted Deten tablets in accordance with local requirements. The medicine must not be flushed down the toilet or poured down a drain; consult local take-back programs or a pharmacist for guidance on proper disposal of pharmaceutical waste.